- Matica Biotechnology, Inc. has announced a strategic development partnership with CytoImmune to advance cell therapy for cancer treatment.
- Matica Bio will produce viral vectors at its GMP facility, while CytoImmune will handle cell therapy manufacturing in Puerto Rico for IND submission.
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) focusing on viral vector manufacturing, has entered into a strategic development partnership with CytoImmune, a biotechnology company based in Puerto Rico. This collaboration aims to advance a clinical cell therapy programme targeting cancer treatments.
Under the terms of the partnership, Matica Bio will produce viral vectors at its purpose-built GMP facility. CytoImmune will manufacture its cell therapy products at its Puerto Rico facility, preparing for submission to the U.S. Food and Drug Administration (FDA) for Investigational New Drug (IND) approval.
Paul Kim, CEO of Matica Bio, stated, “The combined effort to advance a clinical cell therapy program is an exciting opportunity for both organizations.” He highlighted that the collaboration is crucial for mutual growth, leveraging both companies’ expertise in viral vector and cell therapy manufacturing. Matica Bio will provide its capabilities in viral vector process development, GMP production, product release, and stability assessment.
Dr. Jose Vidal, CEO of CytoImmune, added that the partnership would enhance their efforts to deliver innovative therapies that improve patient outcomes. He expressed confidence in Matica Bio’s ability to help streamline processes for accelerated approvals of their therapies.
In addition to this partnership, Matica Bio is collaborating with industry leaders such as Sartorius Stedim Biotech to develop and optimise advanced viral vector manufacturing technologies for large-scale production.
Overview of outsourcing trends 
